Phase I trial of concurrent administration of topotecan and docetaxel for cancer treatment

Docetaxel and topotecan have been used as individual chemotherapy agents in cancer treatment.However,the com- bined effect of these two drugs has not been thoroughly investigated.In a phase I clinical trial,patients previously treat- ed with chemotherapy were treated with concurrent administration of the two drugs;topotecan was administered as a 30-minute infusion,followed by a 30- minute docetaxel infusion.The treat- ment cycle was a bi-weekly regimen with three infusions of topotecan and doc- etaxel (6 weeks in all) followed by a one-week rest.The original protocol started with 3 mg/m 2 of topotecan and 60 mg/m 2 of docetaxel;3 of the 6

[1]  W. Scheithauer,et al.  Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor , 2000, Breast Cancer Research and Treatment.

[2]  A. Milla-Santos,et al.  High-Dose Epirubicin Plus Docetaxel at Standard Dose With Lenograstim Support as First-line Therapy in Advanced Breast Cancer , 2001, American journal of clinical oncology.

[3]  R. Day,et al.  Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Pienta,et al.  Treatment of androgen‐independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study , 2000, The Prostate.

[5]  J. Janinis,et al.  Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. , 2000, American journal of clinical oncology.

[6]  M. Carducci,et al.  Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. , 1999, Seminars in oncology.

[7]  H. Meden,et al.  Docetaxel is effective in the treatment of metastatic endometrial cancer. , 1999, Anticancer research.

[8]  M. Dimopoulos,et al.  Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Dimopoulos,et al.  Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Hainsworth,et al.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Vrignaud,et al.  Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. , 1995, Seminars in oncology.

[12]  J. Verweij,et al.  Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[14]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[15]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.